



The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes

Hædersdal, Sofie; Lund, Asger; Knop, Filip K; Vilsbøll, Tina

Published in:
Mayo Clinic Proceedings

DOI:
[10.1016/j.mayocp.2017.12.003](https://doi.org/10.1016/j.mayocp.2017.12.003)

Publication date:
2018

Document version
Publisher's PDF, also known as Version of record

Document license:
[CC BY-NC-ND](#)

Citation for published version (APA):
Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018). The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes. *Mayo Clinic Proceedings*, 93(2), 217-239.
<https://doi.org/10.1016/j.mayocp.2017.12.003>



The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes

Sofie Hædersdal, MD; Asger Lund, MD, PhD; Filip K. Knop, MD, PhD;
and Tina Vilsbøll, MD, DMSc

Abstract

Type 2 diabetes is a disease involving both inadequate insulin levels and increased glucagon levels. While glucagon and insulin work together to achieve optimal plasma glucose concentrations in healthy individuals, the usual regulatory balance between these 2 critical pancreatic hormones is awry in patients with diabetes. Although clinical discussion often focuses on the role of insulin, glucagon is equally important in understanding type 2 diabetes. Furthermore, an awareness of the role of glucagon is essential to appreciate differences in the mechanisms of action of various classes of glucose-lowering therapies. Newer drug classes such as dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists improve glycemic control, in part, by affecting glucagon levels. This review provides an overview of the effect of glucose-lowering therapies on glucagon on the basis of an extensive PubMed literature search to identify clinical studies of glucose-lowering therapies in type 2 diabetes that included assessment of glucagon. Clinical practice currently benefits from available therapies that impact the glucagon regulatory pathway. As clinicians look to the future, improved treatment strategies are likely to emerge that will either use currently available therapies whose mechanisms of action complement each other or take advantage of new therapies based on an improved understanding of glucagon pathophysiology.

© 2017 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>) ■ Mayo Clin Proc. 2018;93(2):217-239

The opposing actions of insulin and glucagon were demonstrated nearly a century ago.^{1,2} Today, the role of glucagon is recognized as important in glucose homeostasis and diabetes pathophysiology.³⁻⁶ Glucagon, a 29-amino acid peptide hormone, is counterregulatory to insulin, stimulating hepatic glucose production, thereby increasing plasma glucose levels.⁷ Glucagon also stimulates ketogenesis, thus working in tandem with insulin to maintain a normal “fuel balance.”^{8,9} Simply put, insulin acts as a glucose-depositing and anabolic hormone, whereas glucagon is glucose mobilizing and catabolic.^{8,10}

During the past decade, the use of medications that modulate glucagon levels has gradually increased in the treatment of patients with type 2 diabetes (T2D). Dipeptidyl peptidase-4 inhibitors (DPP-4is) and glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), which both suppress glucagon secretion, have received increasing attention as add-on therapies for patients with T2D.^{11,12} Other

glucose-lowering drug classes also affect glucagon secretion (either positively or negatively), including sulfonylureas, exogenous insulin, amylin mimetics, and sodium-glucose cotransporter 2 inhibitors (SGLT2is).

Although plasma glucagon levels are not used in a clinical stratification of diabetic treatment, health care providers may gain clinical insight from understanding how glucagon levels can be pharmacologically controlled in patients with T2D. Of particular interest are the abilities of glucose-lowering drugs to preserve a normal counterregulatory glucagon response in hypoglycemic conditions and, thus, avoid hypoglycemic adverse events. Moreover, as will be discussed, potential benefits can be gained from emerging glucagon-modulating therapeutic strategies.

To explore the relationship between glucagon and T2D, we performed a literature review of glucagon and diabetes, including glucagon in normal physiology and the pathophysiology of T2D. We also made an extensive effort to identify studies that assessed the effect

From the Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark (S.H., A.L., F.K.K., T.V.); Steno Diabetes Center Copenhagen, University of Copenhagen, Gentofte, Denmark (T.V.); Faculty of Health and Medical Sciences, Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark (F.K.K., T.V.); and Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (F.K.K.).

ARTICLE HIGHLIGHTS

- Under normal physiological conditions, glucagon, which is secreted by pancreatic alpha cells, works alongside insulin to regulate plasma glucose levels, including an increase in hepatic glucose production and release of glucose into circulation during hypoglycemia.
- The pathophysiology of type 2 diabetes includes aberrant secretion of glucagon, resulting in elevated glucagon concentrations in both the fasting state and after a meal.
- Some glucose-lowering drug classes, including dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists, decrease glucagon secretion, resulting in amelioration of the inappropriately high glucagon concentrations characteristic of type 2 diabetes and improvement of the insulin:glucagon ratio.
- As clinicians consider treatment strategies for patients with type 2 diabetes, knowledge of the effect of glucose-lowering therapies on glucagon can inform treatment choices.

on glucagon of glucose-lowering drugs within the most commonly used drug classes in current clinical practice. We performed a 2-stage literature search for sulfonylureas, pioglitazone, pramlintide, DPP4-is, GLP-1RAs, and SGLT2is: (1) search of the PubMed database for names of the glucose-lowering drugs and the terms “diabetes” and “glucagon” in the title or abstract (restricted to English-language articles and clinical trials in humans with no date restriction); and (2) assessment of each large, phase 3 clinical trial identified in articles describing each drug’s clinical development program to identify studies in which glucagon levels were measured. For metformin and insulin, a less extensive literature search was conducted that relied primarily on mention of glucagon results in other publications. Although this is neither a systemic nor comprehensive review of all clinical studies with results related to glucagon, the literature search did identify an extensive number of relevant studies.

DISCOVERY OF GLUCAGON AND ITS IMPORTANCE

Glucagon, a peptide hormone,¹³ was identified and named in 1923 when 2 chemists

experimenting with “aqueous extracts of pancreas” found a substance that had a hyperglycemic effect in dogs whose pancreas was removed and in normal rabbits.² Despite the initial confusion about whether glucagon was merely a contaminant during purification of insulin,^{1,5} researchers recognized by the 1950s that glucagon was secreted from pancreatic alpha cells,¹⁴ thus establishing the existence of 2 distinct pancreatic hormones,^{15,16} both responsive to plasma glucose levels.¹⁶ In 1975, Unger and Orci⁹ proposed a “bihormonal hypothesis” of diabetes on the basis of evidence that the metabolic effects of T2D result from absolute or relative hyperglucagonemia, as well as absolute or relative insulin deficiency.⁹ The authors further suggested that controlling glucagon secretion could potentially improve the treatment of diabetes.⁹

A substantial body of evidence suggests that hyperglucagonemia contributes to the hyperglycemic state of patients with T2D.¹⁷⁻²⁰ Although the mechanisms behind diabetic hyperglucagonemia and to what extent it affects the T2D state remain to be elucidated, studies with transgenic mice provide insight into the role of glucagon and its receptor. Transgenic mice lacking the glucagon receptor do not develop diabetes, even after nearly-complete beta-cell destruction.^{21,22} However, this finding has not been confirmed by other groups.²³ Furthermore, transgenic mice with defective leptin receptors develop the phenotype of severe T2D, whereas transgenic mice defective in both glucagon and leptin receptors do not.²⁴ Adenoviral reintroduction of the glucagon receptor in these leptin receptor- and glucagon receptor-deficient mice resulted in severe hyperinsulinemia and hyperglycemia.²⁴

ROLE OF GLUCAGON IN HEALTHY INDIVIDUALS

Normal glucose homeostasis depends largely on balanced secretion of glucagon and insulin from pancreatic alpha and beta cells, respectively, in a tightly regulated, multiloop feedback system (Figure).^{7,25} Following a meal, high plasma glucose levels (hyperglycemia) stimulate the pancreas to release insulin. Insulin promotes glucose uptake and use by insulin-dependent tissues, stimulates formation of glycogen from glucose (glycogenesis) in the liver and muscle, and suppresses glucagon secretion.^{7,25} When plasma glucose levels fall too low




FIGURE. Regulation of blood glucose levels by glucagon and insulin in healthy individuals. In healthy individuals, glucagon and insulin work together to maintain normal plasma glucose levels. During hyperglycemia, pancreatic beta (β) cells release insulin, which stimulates glucose uptake by energy-consuming cells and the formation of glycogen in the liver. During hypoglycemia, pancreatic alpha (α) cells release glucagon, which stimulates gluconeogenesis and glycogenolysis in the liver and the release of glucose to the plasma.

TABLE 1. Factors Regulating Glucagon Secretion⁴³

Stimulatory factors	Inhibitory factors
Hypoglycemia	Carbohydrate meal
Stress	Glucose
Protein meal	Isoleucine ¹⁰
Most amino acids	Nonesterified fatty acids
Some fatty acids ¹⁰	Ketones
Parasympathetic nerves	Gamma-aminobutyric acid ¹⁰
Sympathetic nerves	Adenosine triphosphate
Pituitary adenylate cyclase-activating polypeptide	Zinc ^{3,10}
Cold exposure ⁴⁴	
Stimulatory hormones	Inhibitory hormones
Adrenaline (epinephrine)	Amylin ¹⁰
Cholecystokinin	Glucagon-like peptide-I
Gastrin-releasing peptide	Insulin
Ghrelin ⁴⁵	Leptin ^{46,47}
Glucose-dependent insulintropic polypeptide ⁴⁸	Secretin
Oxytocin	Somatostatin
Vasoactive intestinal peptide	
Vasopressin	
Adapted from <i>Diabetologia</i> , ⁴³ with permission of Springer.	

(hypoglycemia), the pancreas releases glucagon. Upon reaching the liver, glucagon promotes breakdown of glycogen to glucose (glycogenolysis), promotes glucose synthesis (gluconeogenesis), inhibits glycogen formation (glycogenesis), and thus mobilizes export of glucose into the circulation. Thus, glucagon provides a critical response to hypoglycemia. Interestingly, our group recently demonstrated that glucagon is also secreted in patients who have undergone total pancreatectomy, demonstrating extrapancreatic secretion of glucagon in humans.²⁶ The potential implications of this finding for the treatment of T2D are discussed below, though open questions remain: Is extrapancreatic secretion primarily mediated by enteroendocrine cells? Does it occur in both healthy individuals and patients with T2D? Is its metabolic effect physiologically relevant?

Glucagon's physiological role is broader than as a direct counterregulatory hormone to insulin. Glucagon also plays a role in lipid metabolism,²⁷⁻³¹ influences food intake, affects body weight, promotes autophagy, and has pleiotropic effects on the cardiovascular system.³ Notably, many of these glucagon functions are associated with physiological processes awry in T2D. Increasingly, glucagon is recognized for its role in amino acid metabolism³² through

its regulation of hepatic ureagenesis,³³ alteration of transcription of key enzymes in the urea cycle,^{28,34,35} and a probable indirect influence on alpha-cell mass.^{36,37}

In humans, pancreatic islets are composed of approximately 40% alpha and 60% beta cells, whereas the relative proportions in mouse islets are approximately 20% and 80%, respectively, hinting at the relative importance of glucagon secretion.^{10,38} An altered alpha- to beta-cell ratio may be a contributing factor in T2D pathogenesis.^{39,40} Interestingly, glucagon receptor antagonism is associated with alpha-cell proliferation,³⁶ and there is much current interest in transdifferentiation of beta cells from alpha cells.^{39,41,42} In the human pancreas, alpha and beta cells are spatially intermixed, which has important physiological implications because glucagon's effects on insulin-producing beta cells may occur, at least partially, in a paracrine manner.³⁸ The relative hyperglucagonemia of diabetes resulting from an altered alpha- to beta-cell ratio might be a consequence of beta-cell dedifferentiation to glucagon-producing islet cells, greater beta-cell susceptibility to cell apoptosis, and alpha-cell-resistant mechanisms to cellular stress.⁴²

Various factors and hormones modulate glucagon secretion from the pancreatic alpha cell (Table 1).^{3,10,43-48} They may be either stimulatory or inhibitory and involve multiple physiologic pathways. The GLP-1 inhibition of glucagon secretion is particularly noteworthy, because the GLP-1RA class of glucose-lowering drugs mimics the effects of GLP-1.^{49,50} Together, these factors regulate glucagon secretion to prevent the potentially lethal state of hypoglycemia.⁴³

The insulin-glucagon interaction is important in energy homeostasis in the entire body: (1) a high insulin:glucagon ratio promotes biosynthesis of proteins, inhibits glucose production, and reduces release of free fatty acids, whereas (2) a low insulin:glucagon ratio helps the body access stored nutrients, increases hepatic glucose production from glycogen and amino acids, and promotes the breakdown of adipose tissue into free fatty acids and glycerol.⁸ Kalra and Gupta⁵¹ called the insulin:glucagon ratio a "physiological fulcrum," balancing the 2 opposite ends of the metabolic spectrum to conserve energy if possible, but provide it when needed.

The insulin:glucagon ratio determined by measurement of plasma glucagon levels may vary from the portal insulin:glucagon ratio, and conclusions on peripheral measures should always be approached with caution because of higher insulin and glucagon concentrations in portal circulation compared with peripheral.³ Modest changes in insulin and/or glucagon secretion lead to amplified responses on glucose metabolism, in part because of the portal insulin:glucagon ratio. Thus, this provides a strong physiological argument for the rationale of targeting glucagon secretion.

Although studies have not established the utility of measuring glucagon routinely in clinical practice, the insulin:glucagon ratio is a comprehensive metabolic index that has been used for many years in research. Understanding how different drug classes interact with glucagon and how they influence the insulin:glucagon ratio can help to explain the efficacy and safety profiles of such drugs and inform the clinician's choice of treatment agent or potential combinations of treatments.⁵¹

ROLE OF GLUCAGON IN THE PATHOPHYSIOLOGY OF T2D

In patients with T2D, regulation of glucagon secretion is flawed, with elevated plasma glucagon concentrations in the fasting state and defective postprandial glucagon suppression that results in undesirably high plasma glucagon concentrations in the context of hyperglycemia.^{4,6,52,53} Thus, hyperglucagonemia contributes to the increased hepatic glucose output characterizing patients with T2D.^{4,43,54} Furthermore, in patients with T2D, plasma glucagon concentrations may even increase in response to a meal.⁵⁵ Although the mechanisms responsible for elevated glucagon levels in patients with T2D under hyperglycemic conditions are not fully understood, one theory is that pancreatic alpha cells are resistant to the glucagon-suppressive effects of glucose and insulin.^{4,10}

Mechanisms underlying hyperglucagonemia in T2D remain to be fully elucidated. Interestingly, hyperglucagonemia in T2D is aggravated by oral glucose intake but not by intravenous glucose administration, which results in significant glucagon suppression.^{56,57} This suggests that factors originating from

nutrient stimulation of the gastrointestinal tract may play an important role. The recent confirmation that glucagon can be secreted from extrapancreatic tissues constitutes an interesting explanation of the postprandial hyperglucagonemia observed in T2D, namely, that postprandial glucagon production may be gut-derived, not originating from the pancreas.²⁶

An interesting aspect of glucagon pathophysiology in T2D with therapeutic implications is the dynamic nature of the glucagon response to and regulation of both hypoglycemia and hyperglycemia. As will be discussed further below, therapeutic agents shown to have a short-term effect on postprandial glucagon levels (~180 minutes) may not be equally effective over longer treatment periods.

RELEVANCE OF GLUCAGON TO TREATMENT OF T2D AND EFFECTS OF GLUCOSE-LOWERING THERAPIES ON GLUCAGON

Because glucagon has a central role in glucose homeostasis⁷ and patients with T2D have glucagon-mediated elevated hepatic glucose production,^{43,54} addressing the fasting and postprandial hyperglucagonemia of patients with T2D has emerged as an interesting strategy for existing and future glucose-lowering therapies.^{17,19} The introduction of new drug classes that modulate glucagon has underscored the limited attention previously shown to older drug classes in this regard. Table 2^{54,58-168} summarizes the effects of the major classes of glucose-lowering drugs on fasting and postprandial glucagon levels and reports results of less common glucagon assessments, such as those under experimentally induced hypoglycemia.

Older Agents

In general, older therapies have been studied less extensively than newer drug classes regarding effects on glucagon secretion; however, the effect of glucose-lowering drugs on glucagon secretion is becoming more apparent as research in this area expands. In studies with older therapies, results regarding glucagon are often inconsistent, which may be a consequence of variability in study design. Furthermore, the difficulties associated with measuring glucagon should be recognized. Glucagon assays have evolved over time with inconsistencies in both sensitivity and specificity, complicating cross-study comparisons.¹⁶⁹ Cross-reaction with other glucagon-like peptides has

TABLE 2. Summary of Studies Identified That Assess the Effect of Glucose-Lowering Therapies on Glucagon in Patients With Type 2 Diabetes^a

Drug class	Drug	No. of studies ^b	Effect on fasting glucagon	Effect on postprandial glucagon	Additional glucagon measures	Mention in label (PI or SPC)
Older agents						
Biguanides	Metformin ^c	2 Large studies ^{58,59} 2 Small studies ^{60,61}	Significant decrease vs BL ⁵⁸ Decrease vs BL at 52 wk; no effect at 26 wk ⁵⁹ Increase vs PBO ⁶⁰	No effect ⁵⁸	Decrease in glucagon vs BL after administration of oral or IV glucose ⁶⁰ Increase in 12-h plasma glucagon vs glimepiride ⁶¹	None
Insulin	Exogenous insulin ^c	4 Small studies ⁶²⁻⁶⁵	NR	NR	No effect on glucagon response to arginine stimulation ⁶⁵ Decrease in glucagon after arginine stimulation vs pretreatment ⁶⁴ Decrease in plasma glucagon after IV administration of insulin + glucose to fasting patients ⁶³ Significant decrease in 48-h plasma glucagon in insulin-optimized period compared with "uncontrolled" period ⁶²	None
SU	Glyburide/glibenclamide	5 Small studies ⁶⁶⁻⁷¹	NR	No effect after an OGTT ⁷⁰ Nonsignificant increase after meal ⁷¹ No effect vs PBO ⁶⁸	No effect on plasma glucagon (2 studies) ^{68,69} No effect on 24-h plasma glucagon ⁶⁷ Suppressed glucagon secretion during hypoglycemia ⁶⁶	Exerts an inhibitory effect on glucagon-producing alpha cells ⁷²
SU	Glipizide	1 Large study ⁵⁸ 4 Small studies ^{68,73-75}	No effect ⁵⁸ Significant increase vs BL ⁷³	No effect ⁵⁸ No effect vs PBO ⁶⁸ Significant increase after liquid meal challenge ⁷³	No difference in plasma glucagon during hyperglycemic clamp ⁷⁵ No effect on plasma glucagon ⁶⁸ Elevated plasma glucagon ⁷⁴	None

Continued on next page

TABLE 2. Continued

Drug class	Drug	No. of studies ^b	Effect on fasting glucagon	Effect on postprandial glucagon	Additional glucagon measures	Mention in label (PI or SPC)
Older agents, continued						
SU	Gliclazide ^c	7 Small studies ^{70,76-81}	NR	No effect after an OGTT ⁷⁰	No effect on plasma glucagon ^{78,80} No effect during IV glucose tolerance test or arginine test ⁷⁶ No effect on plasma glucagon or in OGTT ⁷⁷ Significant decrease in plasma glucagon during hyperinsulinemic pulse ⁷⁹ No effect on plasma glucagon during glucose infusion ⁸¹	None
SU	Glimepiride	4 Large studies ^{54,82-84} 4 Small studies ^{61,85-88}	No effect (4 studies) ^{83,85,86,88} Increase from BL ⁸²	Increase from BL (2 studies) ^{54,86} No effect ⁸⁷	Decreased 12-h plasma glucagon vs metformin ⁶¹ No effect on plasma glucagon ⁸⁴ Significant increase in glucagon vs BL after arginine stimulation test ⁸⁸	None
TZD	Pioglitazone (Actos)	1 Large study ⁸⁹ 1 Small study ⁹⁰	No effect ⁹⁰	No effect (2 studies) ^{89,90}	None reported	None
Amylin mimetics						
Amylin mimetic	Pramlintide (Symlin)	1 Small study ⁹¹	NR	Decrease ⁹¹	None reported	Suppresses glucagon secretion; reduces postprandial rise in glucagon ⁹²

Continued on next page

TABLE 2. Continued

Drug class	Drug	No. of studies ^b	Effect on fasting glucagon	Effect on postprandial glucagon	Additional glucagon measures	Mention in label (PI or SPC)
DPP-4is						
DPP-4i	Sitagliptin (Januvia)	3 Large studies ^{89,93,94} 4 Medium studies ⁹⁵⁻⁹⁸ 6 Small studies ^{60,88,99-102}	Decrease relative to BL ⁹⁴ No effect (2 studies) ^{60,88}	Significant decrease vs PBO (4 studies) ^{89,93,96,98} Significant decrease vs BL (2 studies) ^{97,100} Decrease, but not vs PBO ⁶⁰ Decrease, but less than with exenatide twice a day ⁹⁵ No change when added to liraglutide ¹⁰² No effect ⁹⁹	No significant change after hyperglycemic clamp ¹⁰¹ Nonsignificant decrease during isoglycemic clamp ⁹⁸	Lowers glucagon secretion from pancreatic alpha cells Decreases glucagon levels in circulation in a glucose-dependent manner After a meal, results in decreased glucagon concentrations ¹⁰³
DPP-4i	Vildagliptin ^d (Galvus/Zomelis)	5 Large studies ^{54,84,104-106} 10 Small studies ^{87,107-115}	No difference vs PBO (4 studies) ^{105,109,111,113} Decrease ¹⁰⁴	Significant decrease vs PBO (8 studies) ^{105-107,109-111,113,114} Significant decrease vs BL ¹⁰⁸ Significant decrease vs glimepiride ⁵⁴ Decrease vs BL Increase, but less than PBO ¹¹²	Increased glucagon during hypoglycemic clamp ¹⁰⁷ No difference vs PBO during hypoglycemic clamp ¹¹² Decreased plasma glucagon ⁸⁴ No difference in AUC ₀₋₂₄ between AM and PM dosing; results similar to PBO ¹¹⁵	Makes pancreas produce less glucagon; enhanced insulin:glucagon ratio during hyperglycemia; enhances the sensitivity of alpha cells to glucose, resulting in more glucose-appropriate glucagon secretion ¹¹⁶
DPP-4i	Saxagliptin (Onglyza)	6 Large studies ¹¹⁷⁻¹²² 1 Small study ¹²³	NR	Significant decrease vs PBO (2 studies) ^{119,122} Decrease vs PBO ¹²¹ Decrease vs glyburide ¹¹⁸ No effect ^{117,120}	Significant decrease vs PBO during IV oral hyperglycemic clamp; decrease during IV hyperglycemic clamp but not significant vs PBO ¹²³	Decreases glucagon after a meal; lowers glucagon secretion from pancreatic alpha cells ¹²⁴
DPP-4i	Linagliptin (Tradjenta/Trajenta)	1 Large study ¹²⁵ 2 Small studies ^{86,126}	No effect ⁸⁶	Decrease (both peak postprandial excursion and area under curve) ¹²⁵ Decrease vs BL ⁸⁶	Increase during hypoglycemia, but not vs PBO ¹²⁶	Lowers glucagon secretion Decreases level of glucagon in circulation ¹²⁷

Continued on next page

TABLE 2. Continued

Drug class	Drug	No. of studies ^b	Effect on fasting glucagon	Effect on postprandial glucagon	Additional glucagon measures	Mention in label (PI or SPC)
DPP-4is, continued						
DPP-4i	Alogliptin (Nesina)	2 Large studies ^{128,129} 2 Medium studies ^{130,131} 1 Small study ¹³²	No effect (2 studies) ^{128,132}	Significant decrease vs PBO (3 studies) ^{128,130,131} Decrease vs BL, but not significant vs PBO ¹²⁹	None reported	Decreases postprandial glucagon ¹³³
GLP-IRAs						
GLP-IRA (short acting)	Exenatide twice a day (Byetta)	4 Large studies ¹³⁴⁻¹³⁷ 2 Medium studies ^{95,97} 6 Small studies ^{88,138-142}	Decrease vs BL (2 studies) ^{136,137} No effect (2 studies) ^{88,140} No difference vs insulin (2 studies) ^{135,141}	Significant decrease vs PBO (3 studies) ^{138,139,142} Significant decrease vs BL (2 studies) ^{95,97} Significant decrease vs sitagliptin (2 studies) ^{95,97} Significant reduction vs insulin glargine postbreakfast, significant increase postlunch ¹⁴¹ No effect ¹⁴⁰	Decreased plasma glucagon ¹³⁴	Suppresses inappropriately elevated glucagon secretion Lowers serum glucagon concentrations during periods of hyperglycemia Does not impair normal glucagon response to hypoglycemia ¹⁴³
GLP-IRA (short acting)	Lixisenatide (Adlyxin/Lyxumia)	2 Large studies ^{144,145} 2 Small studies ^{146,147}	Decrease vs BL ¹⁴⁵	Significant decrease vs PBO ¹⁴⁵ Significant decrease vs liraglutide ¹⁴⁴	No effect on glucagon suppression after IV glucose challenge vs PBO ¹⁴⁵ Significant decrease vs PBO at 3.5 mmol/L glucose; no difference vs PBO at 2.8 mmol/L glucose ¹⁴⁶	Decreases glucagon secretion Decreases postprandial glucagon ¹⁴⁸
GLP-IRA (long acting)	Exenatide QW (Bydureon)	1 Large study ¹³⁶	Decrease vs BL ¹³⁶ Significant decrease vs exenatide twice a day	NR	None reported	Suppresses inappropriately elevated glucagon secretion Moderates glucagon secretion and lowers serum glucagon concentrations during periods of hyperglycemia Does not impair normal glucagon response to hypoglycemia ¹⁴⁹

Continued on next page

TABLE 2. Continued

Drug class	Drug	No. of studies ^b	Effect on fasting glucagon	Effect on postprandial glucagon	Additional glucagon measures	Mention in label (PI or SPC)
GLP-IRAs, continued						
GLP-IRA (long acting)	Liraglutide (Victoza)	7 Large studies ^{82,85,137,144,150-152} 1 Medium study ¹⁵³ 5 Small studies ^{126,154-157}	No effect (2 studies) ^{85,150} Significant decrease vs BL ⁸² Decrease vs BL ¹³⁷ Decrease vs BL, but not significant vs PBO ¹⁵² Significant decrease vs PBO ¹⁵¹ Significant decrease vs PBO at wk 12, but not significant at subsequent visits ¹⁵³	Significant decrease vs PBO (2 studies) ^{155,156} Decrease vs BL ¹⁴⁴ Significant reduction in incremental ratio of postprandial plasma glucagon to BL plasma glucagon, but no effect on postprandial plasma glucagon ¹⁵⁷	Increase during hypoglycemic clamp ¹²⁶ Increase after OGTT at 12 wk but not sustained at wk 24, 36, or 48; delayed time to peak glucagon response ¹⁵³ Significant decrease vs PBO in 24-h glucagon ¹⁵⁴	Decreases glucagon in a glucose-dependent manner. A single dose of liraglutide did not impair glucagon response to low glucose conditions ¹⁵⁸
GLP-IRA (long acting)	Albiglutide (Tanzeum/Eperzan)	1 Large study ¹⁵⁹ 1 Small study ¹⁶⁰	No effect ¹⁵⁹	Decrease, but not significant vs PBO ¹⁵⁹	Significant increase vs PBO during hypoglycemia (glucose clamp 3.3 mmol/L [59.4 mg/dL]); no effect vs PBO during glucose clamp 9.0 mmol/L (162 mg/dL) ¹⁶⁰	Single dose did not impair glucagon response to low glucose concentrations ¹⁶¹
GLP-IRA (long acting)	Dulaglutide (Trulicity)	2 Large studies ^{59,162}	Numeric decrease vs BL; no difference vs insulin glargine ¹⁶² Significant decrease vs metformin at 26 wk; decrease vs BL, but no difference vs metformin at 52 wk ⁵⁹	NR	None reported	Decreases glucagon secretion Decreases fasting glucagon ¹⁶³
GLP-IRA (long acting)	Semaglutide (FDA marketing application filed Dec 2016)	1 Large study ¹⁶⁴	Significant decrease vs PBO ¹⁶⁴	NR	None reported	Not available

Continued on next page

TABLE 2. Continued

Drug class	Drug	No. of studies ^b	Effect on fasting glucagon	Effect on postprandial glucagon	Additional glucagon measures	Mention in label (PI or SPC)
SGLT2is						
SGLT2i	Canagliflozin (Invokana)	No studies identified				None
SGLT2i	Dapagliflozin (Farxiga/ Forxiga)	1 Large study ¹¹⁷ 3 Small studies ¹⁶⁵⁻¹⁶⁷	Significant increase vs BL (2 studies) ^{166,167}	Increase vs BL (2 studies) ^{117,165}	Significant increase in fasting glucagon vs PBO during euglycemic hyperinsulinemic clamp (2 studies) ^{166,167} Significant increase in fasting glucagon:insulin ratio vs BL or PBO (2 studies) ^{166,167}	None
SGLT2i	Empagliflozin (Jardiance)	1 Medium study ¹⁶⁸	Increase vs BL after single dose ¹⁶⁸ Nonsignificant increase vs BL after 4-wk treatment ¹⁶⁸	Significant increase vs BL after single dose and after 4- wk treatment ¹⁶⁸	Decrease in insulin:glucagon ratio after single dose and after 4-wk treatment vs BL ¹⁶⁸	None

^aAUC₀₋₂₄ = area under curve from time 0 to 24 h; BL = baseline; DPP-4i = dipeptidyl peptidase-4 inhibitor; FDA = Food and Drug Administration; GLP-1RA = glucagon-like peptide-1 receptor agonist; IV = intravenous; NR = not reported; OGTT = oral glucose tolerance test; PBO = placebo; PI = prescribing information; QW = once weekly; SGLT2i = sodium-glucose cotransporter 2 inhibitor; SPC = summary of product characteristics; SU = sulfonylurea; TZD = thiazolidinedione.

^bLiterature search for metformin and insulin was less extensive than for other drugs.

^cLarge studies have N ≥ 100, medium studies N = 50 to N < 100, and small studies N < 50.

^dNot marketed in the United States.

been especially challenging regarding specificity, and many assays have not been sensitive enough to detect glucagon levels of less than 10 pmol/L.¹⁶⁹ The study design, lack of studies with older agents and glucagon as a primary end point, and the recognition of unreliable older glucagon assays make it difficult to determine the contribution of the effect of glucagon to the overall pharmacologic profile of the drug.

Metformin has been in use for decades, yet its mechanism of action is not fully understood. As summarized in Table 2, the effect of metformin on glucagon levels varies widely across clinical studies.⁵⁸⁻⁶¹ The primary action of metformin is to decrease hepatic glucose production; this contrasts with the physiologic action of glucagon to stimulate gluconeogenesis in the liver.^{170,171} The overall glucose-lowering effect of metformin is, at least in part, the result of its inhibition of glucagon-induced stimulation of gluconeogenesis rather than its effect on the levels of glucagon or action on insulin.¹⁷² An important murine study demonstrated that metformin acts to antagonize glucagon by affecting the cyclic adenosine monophosphate pathway in hepatocytes,¹⁷³ a finding that has generated much interest in revisiting the mechanism of metformin.

Exogenous insulin is widely used to treat T2D; however, its effects on glucagon levels have not been studied extensively in humans. Although endogenous insulin suppresses glucagon secretion under normal physiologic conditions, the molecular mechanisms of its action are not fully understood.¹⁷⁴ In small mechanistic studies from the 1970s, exogenous insulin was shown to decrease plasma glucagon levels in patients with T2D.⁶²⁻⁶⁴

The primary mechanism of action of sulfonylureas is to increase insulin secretion through effects on beta cells.¹⁷¹ Based on their mechanism of action, a direct effect of sulfonylureas on pancreatic glucagon secretion would not be expected; the bulk of studies examining glucagon secretion are consistent with this view (Table 2).^{58,67-70,75-78,80,81,83-85} However, sulfonylureas did increase fasting and/or postprandial glucagon levels in some studies,^{54,71,73,74,82,86} while decreasing it in 3 others.^{61,66,79} However, in most of the sulfonylurea studies listed in Table 2, measurement of glucagon was not the primary aim of the study, sulfonylurea was often the comparator to another therapy that was the

focus of the study, and any sulfonylurea effects on glucagon that did occur were not interpreted as pharmacologically significant.

Finally, among older agents, pioglitazone, the only thiazolidinedione widely marketed globally, did not have an effect on either fasting or postprandial glucagon concentrations in 2 studies that measured glucagon.^{89,90}

Amylin Mimetics

Pramlintide, the only amylin mimetic marketed in the United States, decreases postprandial glucagon responses.^{91,92,175} This is not unexpected because the hormone amylin inhibits glucagon secretion.^{10,175}

DPP-4is

The DPP-4i and GLP-1RA (discussed later) drug classes have been studied to a greater extent regarding their effects on glucagon than the older drug classes because their effects in this regard are widely recognized.^{12,51,171}

The DPP-4is are “incretin enhancers” that prevent the degradation of endogenously produced glucose-dependent insulinotropic polypeptide and GLP-1, thus extending their action. The GLP-1 is a gut incretin hormone that stimulates pancreatic beta cells to secrete insulin and also suppresses glucagon secretion from the pancreatic alpha cells.¹⁷⁶ Preclinical studies showed that GLP-1 inhibits glucagon release enough to influence physiological glucose regulation.⁴³ Supraphysiological doses of native GLP-1 can restore alpha-cell glucose sensitivity in patients with T2D, facilitating a strict glucose-dependent inhibition of glucagon secretion.¹⁷⁷ Thus, GLP-1 suppresses glucagon secretion during hyperglycemia, with no major role during hypoglycemia. Interestingly, the other incretin hormone, glucose-dependent insulinotropic polypeptide, increases glucagon secretion during hypoglycemic and euglycemic conditions but not during hyperglycemia.¹⁷⁸⁻¹⁸⁰ Consequently, DPP-4is would suppress glucagon secretion during hyperglycemia but not impair glucagon response to hypoglycemia.¹²⁶

Both DPP-4is and GLP-1RAs exert inhibitory actions on glucagon-producing alpha cells that may be, at least partially, responsible for their role in ameliorating T2D. The DPP-4 is expressed in pancreatic islets, almost exclusively in alpha cells in the human pancreas.^{181,182} The DPP-4 localization to alpha cells suggests a direct

effect on alpha cells, implying a paracrine effect on insulin-producing beta cells. Human islets treated with the DPP-4i vildagliptin secreted higher levels of GLP-1 and insulin; thus, the inhibition of islet DPP-4 activity may contribute to the insulinotropic and glucose-lowering action of DPP-4is.¹⁸² Likewise, a local GLP-1 system may exist in human pancreatic islets, with alpha cells containing GLP-1 and the enzyme prohormone convertase 1/3, which has a role in both glucagon and insulin biosynthesis.¹⁸³

In clinical studies, DPP-4is, including sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin, consistently decrease postprandial glucagon secretion compared with the usual glucagon response to a meal, with either no effect or a slightly decreased effect on fasting glucagon (Table 2). Unsurprisingly, given the glucose-dependent effect of the incretin hormones, DPP-4is are glucose dependent in both their action on insulin and glucagon secretion.¹¹

As alluded to earlier, DPP-4is do not affect the normal counterregulatory responses to hypoglycemia.¹¹ In patients with T2D, the normal counterregulatory response to hypoglycemia is impaired because of the hyperglucagonemic characteristic of T2D.⁴ Thus, a therapeutic challenge is to reduce glucagon levels when necessary but, in doing so, not to disrupt the normal, appropriate increase in glucagon in response to hypoglycemia. The effects of DPP-4is on these counterregulatory pathways have been explored in clinical studies that used a “hypoglycemic clamp” to hold plasma glucose at a low target concentration (often by the addition of intravenous insulin).^{107,126} A hypoglycemic clamp study with linagliptin demonstrated no disruption of normal counterregulatory responses to hypoglycemia in patients with T2D.¹²⁶ In contrast, a study of vildagliptin suggests that alpha-cell response to hypoglycemia may even be enhanced by treatment with a DPP-4i.¹⁰⁷ Protection of the counterregulatory response to hypoglycemia may, in part, provide a mechanistic explanation for the low risk of hypoglycemia that is characteristic of both the DPP-4i and GLP-1RA drug classes.^{107,184}

GLP-1RAs

The GLP-1RAs are peptides that act as “incretin mimetics” to increase GLP-1 receptor signaling. They increase postprandial insulin

secretion (even before plasma glucose levels start to rise), inhibit glucagon secretion, slow gastric emptying, and induce satiety. Like DPP-4is, GLP-1RAs are glucose dependent in their action on insulin secretion and their glucagonostatic effect.^{4,11,12}

Clinical studies have generally demonstrated that, similar to DPP-4is, GLP-1RAs substantially lower glucagon concentrations in both the fasting state and after a meal (Table 2), thus reducing the hyperglucagonemia of T2D. Early studies with exenatide twice daily (the first drug marketed in this class) and liraglutide demonstrated reduced postprandial glucagon concentrations in patients with T2D.^{138,139,154} These results have since been confirmed in other mechanistic studies and large clinical trials across the GLP-1RA class. Exenatide twice daily, lixisenatide, exenatide once weekly, liraglutide, and dulaglutide all decrease glucagon secretion.^{59,82,136-139,142-146,148,149,151-158,162,163,171} In addition, semaglutide, a GLP-1RA still in clinical development, decreased fasting glucagon levels in a study.¹⁶⁴

Although GLP-1RAs generally decrease glucagon levels, results are not uniform across the drug class. This may be a consequence of GLP-1RA class members differing in both structure and pharmacokinetic profile. Albiglutide, a large (>600 amino acid) peptide, does not appear to significantly decrease postprandial glucagon, compared with placebo, or to affect the magnitude of the glucagon response in hypoglycemia,^{159,160} likely because it is too large to enter the central nervous system. However, albiglutide affected the timing of the glucagon response to hypoglycemia in a study.¹⁶⁰

Interestingly, long-term treatment (48 weeks) with liraglutide in the Liraglutide and Beta-cell Repair (LIBRA) trial resulted in an increase in glucagon after an oral glucose tolerance test.¹⁵³ Although glucagon enzyme-linked immunosorbent assay cross-reaction with other glucagon-like peptides might possibly contribute to this, the mechanism for this unexpected observation remains unclear and warrants additional study.

In patients with T2D, the glucagon-suppressive effect of GLP-1RAs likely contributes approximately one-third of the overall glucose-lowering effect.^{50,185} Decreased glucagon levels with GLP-1RA treatment result in an increased insulin:glucagon ratio.^{139,153,154} Interestingly, in a

study comparing the short-term effects of the GLP-1RA exenatide twice daily and the DPP-4i sitagliptin, patients treated with exenatide twice daily had significantly lower postprandial glucagon levels than those treated with sitagliptin.⁹⁵ Overall, most studies on the glycemic contribution of the glucagon-lowering ability of GLP-1RAs are based on short-term effects, whereas data on chronic effects of GLP-1RAs on glucagon suppression are scarce and need to be investigated further.

The effects of GLP-1RA on the physiological counterregulatory response during hypoglycemia have been explored in clinical studies using a hypoglycemic clamp, similar to the studies described for DPP-4is. These studies demonstrated no disruption of normal counterregulatory responses to hypoglycemia in patients with T2D by GLP-1RAs, including lixisenatide,¹⁸⁶ albiglutide,¹⁶⁰ and liraglutide.¹²⁶ In addition, exenatide did not disrupt these responses in healthy volunteers.¹⁸⁴ In summary, GLP-1RAs decrease inappropriately elevated glucagon levels but do not impair the counterregulatory response of glucagon to hypoglycemia.

SGLT2is

The SGLT2i class of glucose-lowering drugs prevents reabsorption of glucose in the kidney, which facilitates the excretion of glucose in urine and, in turn, reduces plasma glucose levels.^{171,187} Because these actions are insulin independent, there is minimal potential for hypoglycemia.¹⁸⁷ Results from clinical studies examining the effects of treatment with dapagliflozin^{117,165-167} and empagliflozin¹⁶⁸ on glucagon secretion demonstrated increased fasting glucagon and postprandial glucagon levels and decreased insulin:glucagon ratios. To our knowledge, no clinical studies have reported the effects of canagliflozin on glucagon (Table 2).

Although there is limited information in humans regarding whole-body metabolic adaptation to treatment with SGLT2is,¹⁸⁸ 2 independent research teams uncovered an apparent SGLT2i class effect. Although SGLT2is lower fasting glucose in patients with T2D, they elicit a paradoxical rise in endogenous glucose production.^{167,168} Merovci et al¹⁶⁷ found that dapagliflozin induced glucosuria and improved peripheral insulin sensitivity; however, endogenous glucose production increased substantially and was

accompanied by an increase in fasting plasma glucagon concentration. In the other study, Ferrannini et al¹⁶⁸ reported that patients exhibited glycosuria after empagliflozin treatment, but empagliflozin was also associated with increased endogenous glucose production, beta-cell glucose sensitivity, and postprandial glucagon response.¹⁶⁸ Notably, studies measuring glucagon are often of short duration and may not provide insight into longer-term glucagon effects. In the Ferrannini et al study, the magnitude of the glucagon increase after 4 weeks of treatment was decreased compared with the increase after a single dose.¹⁶⁸

Thus, it appears that SGLT2is may have a direct effect on glucagon in T2D. Merovci et al¹⁶⁷ speculate on several potential mechanisms for the relative increase in glucagon after SGLT2i treatment: acute decline in insulin-induced plasma glucose concentration from one hyperglycemic level to a lower hyperglycemic level; activation of a neural reflex that connects the kidney directly with pancreatic alpha cells; or activation of neuronal centers in the central nervous system that communicate with the alpha cells.¹⁶⁷ Two mechanistic studies provide insight into the increase in glucagon secretion with SGLT2i treatment via a direct effect on SGLT2 expression found in pancreatic alpha cells.^{189,190} The SGLT2is have been associated with an increased risk of diabetic ketoacidosis.¹⁹¹ The SGLT2i-induced increase in glucagon may provide a partial explanation for this observation given that increased levels of glucagon are linked with diabetic ketoacidosis.¹⁹²

FUTURE OF DIABETES TREATMENT RELATED TO GLUCAGON

On the basis of findings described above, Merovci et al,¹⁶⁷ among others, have suggested that the combination of an SGLT2i and an incretin-based therapy could provide a potential synergism for the treatment of patients with T2D.^{51,167,193,194} The rationale is that the incretin-based drug would block the increased production of endogenous glucose and elevated glucagon levels associated with SGLT2is and enhance the glucose-lowering effect of the SGLT2i.^{167,193} A number of studies have reported a reduction in glucose (glycated hemoglobin [A1C]) levels after treatment with the

TABLE 3. Randomized Phase 3 Clinical Studies That Combine Either a DPP-4i or a GLP-1RA With an SGLT2i in the Treatment of Type 2 Diabetes^a

Reference, year	Duration to end point	Background therapy	Treatment arms	n	Change from baseline in A1C (%) [mmol/mol] ^b
DPP-4i + SGLT2i ^c					
Lewin et al, ¹⁹⁵ 2015	24 wk	None	Linagliptin 5 mg + empagliflozin 10 mg	135	−1.24 ± 0.06 [−13.6 ± 0.7]
			Linagliptin 5 mg + empagliflozin 25 mg	134	−1.08 ± 0.06 [−11.8 ± 0.7]
			Linagliptin 5 mg	133	−0.67 ± 0.06 [−7.3 ± 0.7]
			Empagliflozin 10 mg	132	−0.83 ± 0.6 [−9.1 ± 0.7]
			Empagliflozin 25 mg	133	−0.95 ± 0.06 [−10.4 ± 0.7]
DeFronzo et al, ¹⁹⁶ 2015	24 wk	Metformin	Linagliptin 5 mg + empagliflozin 10 mg	135	−1.08 ± 0.06 [−11.8 ± 0.7]
			Linagliptin 5 mg + empagliflozin 25 mg	134	−1.19 ± 0.06 [−13.1 ± 0.7]
			Linagliptin 5 mg	128	−0.70 ± 0.06 [−7.6 ± 0.7]
			Empagliflozin 10 mg	137	−0.66 ± 0.06 [−7.2 ± 0.7]
			Empagliflozin 25 mg	140	−0.62 ± 0.06 [−6.8 ± 0.7]
Rosenstock et al, ¹⁹⁷ 2015	24 wk	Metformin	Saxagliptin 5 mg + dapagliflozin 10 mg	179	−1.47 ± 0.08 ^d [−16.1 ± 0.9]
			Saxagliptin 5 mg	176	−0.88 ± 0.08 [−9.6 ± 0.9]
			Dapagliflozin 10 mg	179	−1.20 ± 0.08 [−13.1 ± 0.9]
Mathieu et al, ¹⁹⁸ 2015	24 wk	Metformin	Dapagliflozin 10 mg + saxagliptin 5 mg	146	−0.82 ^d ± 0.07 [−9.0 ^d ± 0.8]
Matthaei et al, ¹⁹⁹ 2015	24 wk	Metformin	Placebo + saxagliptin	129	−0.10 ± 0.07 [−1.1 ± 0.8]
			Saxagliptin + dapagliflozin 10 mg	139	−0.51 ^d (−0.63 to −0.39) [−5.6 ^d (−6.9 to −4.3)]
			Placebo + dapagliflozin 10 mg	149	−0.16 ^d (−0.28 to −0.04) [−1.7 ^d (−3.1 to −0.04)]
Mathieu et al, ²⁰⁰ 2016	52 wk	Metformin	Dapagliflozin 10 mg + saxagliptin 5 mg	160	−0.74 ^d (−0.90 to −0.57) [−8.1 ^d (−9.8 to −6.2)]
			Placebo + saxagliptin 5 mg	160	+0.07 ^d (−0.13 to +0.27) [−0.8 ^d (−1.4 to −3.0)]
Jabbour et al, ²⁰¹ 2014	24 wk	± Metformin	Dapagliflozin 10 mg + sitagliptin 100 mg	223	−0.5 (−0.6 to −0.4) ^e [−4.9 (−6.0 to −3.8)]
			Placebo + sitagliptin 100 mg	224	0.0 (−0.1 to +0.1) [+0.4 (−0.7 to +1.5)]
GLP-1RA + SGLT2i					
Frías et al, ²⁰² 2016 (DURATION-8)	28 wk	Metformin	Exenatide 2 mg QW + dapagliflozin 10 mg every day	228	−2.0 (−2.1 to −1.8) [−21.9 (−23.0 to −19.7)]
			Exenatide 2 mg QW	227	−1.6 (−1.8 to −1.4) [−17.5 (−19.7 to −15.3)]
			Dapagliflozin 10 mg every day	230	−1.4 (−1.6 to −1.2) [−15.3 (−17.5 to −13.1)]

^aA1C = glycated hemoglobin; DPP-4i = dipeptidyl peptidase-4 inhibitor; DURATION-8 = Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors Through Intervention with Exenatide Once Weekly-8; GLP-1RA = glucagon-like peptide-1 receptor agonist; QW = once weekly; SGLT2i = sodium-glucose cotransporter 2 inhibitor.

^bData are presented as mean ± standard error or mean (95% CI).

^cDosing of DPP-4i and SGLT2i was once daily in all DPP-4i + SGLT2i studies.

^dAdjusted mean.

^eLast observation carried forward analysis.

combination of an SGLT2i and either a DPP-4i or a GLP-1RA (Table 3).¹⁹⁵⁻²⁰²

Combination of DPP-4i and SGLT2i

To our knowledge, only 1 post hoc analysis has examined the effect of 1 of these combination treatments on glucagon in patients with T2D.¹¹⁷ Glucagon levels increased approximately 10% after a liquid meal tolerance test with dapagliflozin treatment but did not increase with saxagliptin or the combination of saxagliptin and dapagliflozin. Interestingly, the change in glucagon levels did not correlate with changes in A1C levels.

Several large clinical studies have demonstrated that the combination of a DPP-4i and an SGLT2i improves glycemic control in patients with T2D (Table 3).^{117,195-201} In each study, the DPP-4i/SGLT2i combination resulted in a greater A1C decrease than each drug alone: this was true for the combinations of linagliptin and empagliflozin,^{195,196} saxagliptin and dapagliflozin,¹⁹⁷⁻²⁰⁰ and sitagliptin and dapagliflozin.²⁰⁰ Notably, although the combination of linagliptin and empagliflozin^{195,196} and the combination of saxagliptin and dapagliflozin¹⁹⁷ resulted in greater A1C decreases than the individual drugs and a significant increase in the proportion of patients attaining a target A1C of less than 7.0%, in each case, the reductions in A1C were less than additive.¹⁹⁵⁻¹⁹⁷

Combination of GLP-1RA and SGLT2i

Similar to the results from studies of DPP-4i/SGLT2i combinations, GLP-1RA/SGLT2i combination treatment was more effective than either drug alone in reducing glucose (Table 3); however, none of these studies reported glucagon results.

The combination of a GLP-1RA and an SGLT2i has, to our knowledge, been studied in only 1 phase 3 trial. In the DURATION (Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors Through Intervention with Exenatide Once Weekly)-8 study, the combination of exenatide once weekly and dapagliflozin significantly reduced A1C levels from baseline compared with either drug alone, although the effects were not additive.²⁰²

Results from the DURATION-8 study are consistent with findings from previous small studies and post hoc analyses of GLP-1RA/SGLT2i combinations in T2D.²⁰³⁻²⁰⁵ In each

of these studies, the addition of an SGLT2i to a GLP-1RA augmented A1C reductions compared with the GLP-1RA alone. Similarly, the combination of daily dapagliflozin and exenatide once weekly was significantly more effective than placebo in improving body weight and reducing the risk of prediabetes than either drug alone.²⁰⁶ Ongoing large clinical studies are examining the effects of adding liraglutide to canagliflozin (NCT02324842)²⁰⁷ or dulaglutide to SGLT2is (AWARD-10 [A Study of Dulaglutide in Participants with Type 2 Diabetes Mellitus]; NCT02597049).²⁰⁸

Antagonism of the Glucagon Receptor

Antagonism of the glucagon receptor is being investigated in another approach for treating T2D.²⁰⁹ Inhibiting glucagon-induced hepatic glucose production should, in theory, effectively decrease both fasting and postprandial hyperglycemia.⁴ In a murine model of T2D, treatment with a glucagon receptor antagonist normalized plasma glucose and A1C levels to within nondiabetic ranges.^{210,211} Phase 2 clinical studies have demonstrated reduced glycemia in patients with T2D treated with 2 glucagon receptor antagonists, LY2409021²¹² and PF-06291874.²¹³ Despite good effect on glycemic end points, no drug in this class has reached the market for the treatment of T2D. This may be a consequence, in part, of observations that glucagon receptor antagonism results in elevation of liver transaminases,^{4,212-215} liver fat,^{216,217} body weight,^{4,214} systolic blood pressure,²¹⁵ low-density lipoprotein cholesterol levels,^{214,215} and alpha-cell hyperplasia.²⁰⁹ The mechanisms for these side effects have been investigated, and though yet unknown, the mechanism for the increase in transaminase levels might be a result of increases in hepatic fat content (triglycerides).²¹³ Glucagon receptor antagonists have been associated with increased cholesterol absorption from the gut.²¹⁸

Glucagon Receptor/GLP-1 Receptor Coagonists

Another emerging therapeutic strategy for the treatment of T2D and associated obesity that capitalizes on the underlying pathophysiology of glucagon is coagonism of the glucagon and GLP-1 receptors by a single molecule, of which there are now several examples with

experimental evidence in rodent models.²¹⁹⁻²²²

Readers are directed to the excellent review by Müller et al³ and references therein for a fuller discussion than space allows here.

CONCLUSION

To normalize metabolic control of glucose in the treatment of T2D, support has increased for targeting not only abnormalities in insulin secretion but also dysfunctional glucagon secretion. Glucagon is a key regulator of normal fuel metabolism, and both fasting and postprandial hyperglucagonemia make substantial contributions to the fasting hyperglycemia and postprandial glucose excursions that characterize T2D. Because patients with T2D have defects in glucagon control, improved restoration of metabolic control by therapies that also suppress glucagon, including DPP-4is and GLP-1RAs, would be beneficial. Future studies should focus on how novel strategies such as glucagon antagonism, glucagon/GLP-1 receptor coagonism, or combining DPP-4is or GLP-1RAs with SGLT2is can best control both insulin and glucagon in patients with T2D.

ACKNOWLEDGMENTS

Elizabeth Strickland, PhD, of inScience Communications, Springer Healthcare (Philadelphia, PA), and Faith Reidenbach, on behalf of inScience Communications, provided medical writing support, which was funded by AstraZeneca.

Abbreviations and Acronyms: A1C = glycated hemoglobin; DPP-4i = dipeptidyl peptidase-4 inhibitor; DURATION-8 = Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors Through Intervention with Exenatide Once Weekly-8; GLP-1 = glucagon-like peptide-1; GLP-1RA = glucagon-like peptide-1 receptor agonist; SGLT2i = sodium-glucose cotransporter 2 inhibitor; T2D = type 2 diabetes

Grant Support: Medical writing support was funded by AstraZeneca.

Potential Competing Interests: Dr Hædersdal has no conflicts of interest to disclose. Within the past 36 months, Dr Lund has served as a consultant for Novo Nordisk. Within the past 36 months, Dr Knop has served on scientific advisory panels and/or speakers bureaus for, served as a consultant to, and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Fractyl, Gubra, Merck Sharp & Dohme, Novo Nordisk,

Sanofi, and Zealand Pharma. Within the past 36 months, Dr Vilsbøll has served on scientific advisory panels and/or speakers bureaus for, served as a consultant to, and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Merck Sharp & Dohme, Novo Nordisk, Sanofi, and Takeda.

Correspondence: Address to Tina Vilsbøll, MD, DMSc, Steno Diabetes Center Copenhagen, University of Copenhagen, Niels Steensens Vej 2, DK-2820 Gentofte, Denmark (t.vilsboll@dadlnet.dk).

REFERENCES

1. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the treatment of diabetes mellitus. *Can Med Assoc J*. 1922;12(3):141-146.
2. Kimball CP, Murlin JR. Aqueous extracts of pancreas, III: some precipitation reactions of insulin. *J Biol Chem*. 1923;58:337-346.
3. Müller TD, Finan B, Clemmensen C, DiMarchi RD, Tschöp MH. The new biology and pharmacology of glucagon. *Physiol Rev*. 2017;97(2):721-766.
4. Lund A, Bagger JL, Christensen M, Knop FK, Vilsbøll T. Glucagon and type 2 diabetes: the return of the alpha cell. *Curr Diab Rep*. 2014;14(12):555.
5. Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. *J Clin Invest*. 2012;122(1):4-12.
6. Ceriello A, Genovese S, Mannucci E, Gronda E. Glucagon and heart in type 2 diabetes: new perspectives. *Cardiovasc Diabetol*. 2016;15(1):123.
7. Unger RH, Orci L. Glucagon and the A cell: physiology and pathophysiology (first of two parts). *N Engl J Med*. 1981;304(25):1518-1524.
8. Unger RH. Glucagon and the insulin: glucagon ratio in diabetes and other catabolic illnesses. *Diabetes*. 1971;20(12):834-838.
9. Unger RH, Orci L. The essential role of glucagon in the pathogenesis of diabetes mellitus. *Lancet*. 1975;1(7897):14-16.
10. Quesada I, Tudurí E, Ripoll C, Nadal A. Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes. *J Endocrinol*. 2008;199(1):5-19.
11. Nauck MA, Vilsbøll T, Gallwitz B, Garber A, Madsbad S. Incretin-based therapies: viewpoints on the way to consensus. *Diabetes Care*. 2009;32(Suppl 2):S223-S231.
12. Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. *Diabetes Obes Metab*. 2016;18(3):203-216.
13. Unger RH, Aguilar-Parada E, Müller WA, Eisentraut AM. Studies of pancreatic alpha cell function in normal and diabetic subjects. *J Clin Invest*. 1970;49(4):837-848.
14. Sutherland EW, De Duve C. Origin and distribution of the hyperglycemic-glycogenolytic factor of the pancreas. *J Biol Chem*. 1948;175(2):663-674.
15. Foa PP, Santamaria L, Weinstein HR, Berger S, Smith JA. Secretion of the hyperglycemic-glycogenolytic factor in normal dogs. *Am J Physiol*. 1952;171(1):32-36.
16. Staub A, Sinn L, Behrens OK. Purification and crystallization of glucagon. *J Biol Chem*. 1955;214(2):619-632.
17. Shah P, Basu A, Basu R, Rizza R. Impact of lack of suppression of glucagon on glucose tolerance in humans. *Am J Physiol*. 1999;277(2, Pt 1):E283-E290.
18. Dunning BE, Gerich JE. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. *Endocr Rev*. 2007;28(3):253-283.
19. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial

- hyperglycemia in subjects with type 2 diabetes mellitus. *J Clin Endocrinol Metab*. 2000;85(11):4053-4059.
20. Bagger JJ, Knop FK, Holst JJ, Vilsbøll T. Glucagon antagonism as a potential therapeutic target in type 2 diabetes. *Diabetes Obes Metab*. 2011;13(11):965-971.
 21. Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. *Diabetes*. 2011;60(2):391-397.
 22. Conarello SL, Jiang G, Mu J, et al. Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. *Diabetologia*. 2007;50(1):142-150.
 23. Steenberg VR, Jensen SM, Pedersen J, et al. Acute disruption of glucagon secretion or action does not improve glucose tolerance in an insulin-deficient mouse model of diabetes. *Diabetologia*. 2016;59(2):363-370.
 24. Lee Y, Berglund ED, Yu X, et al. Hyperglycemia in rodent models of type 2 diabetes requires insulin-resistant alpha cells. *Proc Natl Acad Sci U S A*. 2014;111(36):13217-13222.
 25. Sandoval DA, D'Alessio DA. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. *Physiol Rev*. 2015;95(2):513-548.
 26. Lund A, Bagger JJ, Wewer Albrechtsen NJ, et al. Evidence of extrapancreatic glucagon secretion in man. *Diabetes*. 2016;65(3):585-597.
 27. Charron MJ, Vuguin PM. Lack of glucagon receptor signaling and its implications beyond glucose homeostasis. *J Endocrinol*. 2015;224(3):R123-R130.
 28. Watanabe C, Seino Y, Miyahira H, et al. Remodeling of hepatic metabolism and hyperaminoacidemia in mice deficient in proglucagon-derived peptides. *Diabetes*. 2012;61(1):74-84.
 29. Longuet C, Sinclair EM, Maida A, et al. The glucagon receptor is required for the adaptive metabolic response to fasting. *Cell Metab*. 2008;8(5):359-371.
 30. von Meyenn F, Porstmann T, Gasser E, et al. Glucagon-induced acetylation of Foxa2 regulates hepatic lipid metabolism. *Cell Metab*. 2013;17(3):436-447.
 31. Berglund ED, Kang L, Lee-Young RS, et al. Glucagon and lipid interactions in the regulation of hepatic AMPK signaling and expression of PPARalpha and FGF21 transcripts in vivo. *Am J Physiol Endocrinol Metab*. 2010;299(4):E607-E614.
 32. Wewer Albrechtsen NJ, Kuhre RE, Pedersen J, Knop FK, Holst JJ. The biology of glucagon and the consequences of hyperglucagonemia. *Biomark Med*. 2016;10(11):1141-1151.
 33. Almdal TP, Holst JJ, Heindorff H, Vilstrup H. Glucagon immunoneutralization in diabetic rats normalizes urea synthesis and decreases nitrogen wasting. *Diabetes*. 1992;41(1):12-16.
 34. Heibel SK, Lopez GY, Panglao M, et al. Transcriptional regulation of N-acetylglutamate synthase. *PLoS One*. 2012;7(2):e29527.
 35. Takiguchi M, Mori M. Transcriptional regulation of genes for ornithine cycle enzymes. *Biochem J*. 1995;312(Pt 3):649-659.
 36. Solloway MJ, Madjid A, Gu C, et al. Glucagon couples hepatic amino acid catabolism to mTOR-dependent regulation of alpha-cell mass. *Cell Rep*. 2015;12(3):495-510.
 37. Longuet C, Robledo AM, Dean ED, et al. Liver-specific disruption of the murine glucagon receptor produces alpha-cell hyperplasia: evidence for a circulating alpha-cell growth factor. *Diabetes*. 2013;62(4):1196-1205.
 38. Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren PO, Caicedo A. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. *Proc Natl Acad Sci U S A*. 2006;103(7):2334-2339.
 39. Godoy-Matos AF. The role of glucagon on type 2 diabetes at a glance. *Diabetol Metab Syndr*. 2014;6(1):91.
 40. Dor Y, Glaser B. Beta-cell dedifferentiation and type 2 diabetes. *N Engl J Med*. 2013;368(6):572-573.
 41. Chakravarthy H, Gu X, Enge M, et al. Converting adult pancreatic islet alpha cells into beta cells by targeting both Dnm1 and Arx. *Cell Metab*. 2017;25(3):622-634.
 42. Wali JA, Thomas HE. Pancreatic alpha cells hold the key to survival. *EBioMedicine*. 2015;2(5):368-369.
 43. Dunning BE, Foley JE, Ahren B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. *Diabetologia*. 2005;48(9):1700-1713.
 44. Seitz HJ, Krone W, Wilke H, Tamowski W. Rapid rise in plasma glucagon induced by acute cold exposure in man and rat. *Pflugers Arch*. 1981;389(2):115-120.
 45. Adeghate E, Parvez H. Mechanism of ghrelin-evoked glucagon secretion from the pancreas of diabetic rats. *Neuro Endocrinol Lett*. 2002;23(5-6):432-436.
 46. Yu X, Park BH, Wang MY, Wang ZV, Unger RH. Making insulin-deficient type 1 diabetic rodents thrive without insulin. *Proc Natl Acad Sci U S A*. 2008;105(37):14070-14075.
 47. Wang MY, Chen L, Clark GO, et al. Leptin therapy in insulin-deficient type 1 diabetes. *Proc Natl Acad Sci U S A*. 2010;107(11):4813-4819.
 48. Meier JJ, Gallwitz B, Siepmann N, et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. *Diabetologia*. 2003;46(6):798-801.
 49. Ritzel R, Orskov C, Holst JJ, Nauck MA. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers: dose-response-relationships. *Diabetologia*. 1995;38(6):720-725.
 50. Hare KJ, Vilsbøll T, Asmar M, Deacon CF, Knop FK, Holst JJ. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. *Diabetes*. 2010;59(7):1765-1770.
 51. Kalra S, Gupta Y. The insulin:glucagon ratio and the choice of glucose-lowering drugs. *Diabetes Ther*. 2016;7(1):1-9.
 52. Müller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes: response to carbohydrate and protein ingestion. *N Engl J Med*. 1970;283(3):109-115.
 53. Mitrakou A, Kelley D, Veneman T, et al. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. *Diabetes*. 1990;39(11):1381-1390.
 54. Ahren B, Foley JE, Ferrannini E, et al. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. *Diabetes Care*. 2010;33(4):730-732.
 55. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. *J Clin Endocrinol Metab*. 1987;64(1):106-110.
 56. Knop FK, Vilsbøll T, Madsbad S, Holst JJ, Krarup T. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. *Diabetologia*. 2007;50(4):797-805.
 57. Bagger JJ, Knop FK, Lund A, Holst JJ, Vilsbøll T. Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals. *Diabetologia*. 2014;57(8):1720-1725.
 58. Bi Y, Tong GY, Yang HJ, et al. The beneficial effect of metformin on beta-cell function in non-obese Chinese subjects with newly diagnosed type 2 diabetes. *Diabetes Metab Res Rev*. 2013;29(8):664-672.
 59. Umpierrez G, Tofé Povedano S, Pérez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). *Diabetes Care*. 2014;37(8):2168-2176.
 60. Vardarli I, Amdt E, Deacon CF, Holst JJ, Nauck MA. Effects of sitagliptin and metformin treatment on incretin hormone and

- insulin secretory responses to oral and "isoglycemic" intravenous glucose. *Diabetes*. 2014;63(2):663-674.
61. Machado HA, Vieira M, Cunha MR, et al. Metformin, but not glimepiride, improves carotid artery diameter and blood flow in patients with type 2 diabetes mellitus. *Clinics (Sao Paulo)*. 2012;67(7):711-717.
62. Raskin P, Unger RH. Effect of insulin therapy on the profiles of plasma immunoreactive glucagon in juvenile-type and adult-type diabetics. *Diabetes*. 1978;27(4):411-419.
63. Raskin P, Fujita Y, Unger RH. Effect of insulin-glucose infusions on plasma glucagon levels in fasting diabetics and nondiabetics. *J Clin Invest*. 1975;56(5):1132-1138.
64. Ohneda A, Ishii S, Horigome K, Yamagata S. Glucagon response to arginine after treatment of diabetes mellitus. *Diabetes*. 1975;24(9):811-819.
65. Raskin P, Aydin I, Unger RH. Effect of insulin on the exaggerated glucagon response to arginine stimulation in diabetes mellitus. *Diabetes*. 1976;25(3):227-229.
66. Landstedt-Hallin L, Adamson U, Lins PE. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. *J Clin Endocrinol Metab*. 1999;84(9):3140-3145.
67. Prosser PR, Kosola JW, Bowers CY. The 24-hour effects of glyburide and chlorpropamide after chronic treatment of type II diabetic patients. *Am J Med Sci*. 1985;289(5):179-185.
68. Groop L, Wåhlin-Boll E, Groop PH, et al. Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics. *Eur J Clin Pharmacol*. 1985;28(6):697-704.
69. Groop L, Hamo K, Nikkilä EA, Pelkonen R, Tolppanen EM. Transient effect of the combination of insulin and sulfonylurea (glibenclamide) on glycemic control in non-insulin dependent diabetics poorly controlled with insulin alone. *Acta Med Scand*. 1985;217(1):33-39.
70. Fukase N, Manaka H, Sugiyama K, et al. Response of truncated glucagon-like peptide-I and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus: effect of sulfonylurea therapy. *Acta Diabetol*. 1995;32(3):165-169.
71. Gutniak M, Karlander SG, Efendić S. Glyburide decreases insulin requirement, increases beta-cell response to mixed meal, and does not affect insulin sensitivity: effects of short- and long-term combined treatment in secondary failure to sulfonylurea. *Diabetes Care*. 1987;10(5):545-554.
72. Daonil (glibenclamide) [product information]. Auckland, New Zealand: Sanofi-Aventis New Zealand Limited; 2016.
73. Mooradian AD, Albert SG, Bernbaum M, Plummer S. The effect of glipizide gastrointestinal therapeutic system on islet cell hormonal responses to a test meal in NIDDM. *Diabetes Care*. 1996;19(8):883-884.
74. Lecomte MJ, Luyckx AS, Lefebvre PJ. Plasma glucagon and clinical control of maturity-onset type diabetes: effects of diet, placebo and glipizide. *Diabetes Metab*. 1977;3(4):239-243.
75. Aaboe K, Knop FK, Vilsbøll T, et al. KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. *J Clin Endocrinol Metab*. 2009;94(2):603-608.
76. Brogard JM, Pinget M, Dornier M. Effect of middle-term gliclazide treatment on insulin secretion in non-insulin dependent diabetics. *Curr Med Res Opin*. 1984;9(1):56-63.
77. Couturier E. Gliclazide on long-term therapy increases insulin response to glucose of type II diabetics. *Diabetes Res Clin Pract*. 1985-1986;1(6):343-347.
78. Hissa MR, Cavalcante LL, Guimaraes SB, Hissa MN. A 16-week study to compare the effect of vildagliptin versus gliclazide on postprandial lipoprotein concentrations and oxidative stress in patients with type 2 diabetes inadequately controlled with metformin monotherapy. *Diabetol Metab Syndr*. 2015;7:62.
79. Juhl CB, Parksen N, Pincus SM, Hansen AP, Veldhuis JD, Schmitz O. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes. *Diabetes*. 2001;50(8):1778-1784.
80. Kilo C, Dudley J, Kalb B. Evaluation of the efficacy and safety of Diamicon in non-insulin-dependent diabetic patients. *Diabetes Res Clin Pract*. 1991;14(Suppl 2):S79-S82.
81. Riccio A, Lisato G, de Kreutzenberg SV, et al. Gliclazide potentiates suppression of hepatic glucose production in non-insulin-dependent diabetic patients. *Metabolism*. 1996;45(10):1196-1202.
82. Garber A, Henry R, Ratner R, et al; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. *Lancet*. 2009;373(9662):473-481.
83. Burant CF, Viswanathan P, Marcinkak J, et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. *Lancet*. 2012;379(9824):1403-1411.
84. Derosa G, Bonaventura A, Bianchi L, et al. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. *Metabolism*. 2014;63(7):957-967.
85. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211-1310 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. *Diabetes Care*. 2004;27(6):1335-1342.
86. Forst T, Anastasiadis E, Diessel S, Löffler A, Pfützner A. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment. *Diabetes Metab Res Rev*. 2014;30(7):582-589.
87. He YL, Foteinos G, Neelakantham S, et al. Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring. *Diabetes Obes Metab*. 2013;15(12):1111-1119.
88. Gudipaty L, Rosenfeld NK, Fuller CS, Gallop R, Schutta MH, Rickels MR. Effect of exenatide, sitagliptin, or glimepiride on beta-cell secretory capacity in early type 2 diabetes. *Diabetes Care*. 2014;37(9):2451-2458.
89. Alba M, Ahren B, Inzucchi SE, et al. Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function. *Diabetes Obes Metab*. 2013;15(12):1101-1110.
90. Gastaldello A, Casolaro A, Pettiti M, et al. Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes. *Clin Pharmacol Ther*. 2007;81(2):205-212.
91. Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. *Horm Metab Res*. 2002;34(9):504-508.
92. Symlin (pramlintide acetate) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2015.
93. Derosa G, Carbone A, D'Angelo A, et al. Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin. *Intern Med*. 2013;52(19):2179-2187.
94. Lim S, An JH, Shin H, et al. Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study. *Clin Endocrinol (Oxf)*. 2012;77(2):215-223.
95. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion,

- gastric emptying, and caloric intake: a randomized, cross-over study. *Curr Med Res Opin.* 2008;24(10):2943-2952.
96. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. *J Clin Endocrinol Metab.* 2006;91(11):4612-4619.
 97. Berg JK, Shenouda SK, Heilmann CR, Gray AL, Holcombe JH. Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study. *Diabetes Obes Metab.* 2011;13(11):982-989.
 98. Muscelli E, Casolaro A, Gastaldelli A, et al. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. *J Clin Endocrinol Metab.* 2012;97(8):2818-2826.
 99. Jung JA, Kaku K, Kim JH, et al. Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitus. *Adv Ther.* 2013;30(11):1018-1029. Erratum in *Adv Ther.* 2014;31(1):149.
 100. Murai K, Katsuno T, Miyagawa J, et al. Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data. *Drugs R D.* 2014;14(4):301-308.
 101. Stafford S, Elahi D, Meneilly GS. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus. *J Am Geriatr Soc.* 2011;59(6):1148-1149.
 102. Nauck MA, Kahle M, Baranov O, Deacon CF, Holst JJ. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: a randomized controlled trial in patients with type 2 diabetes. *Diabetes Obes Metab.* 2017;19(2):200-207.
 103. Januvia (sitagliptin) [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc; 2015.
 104. Derosa G, Ragonesi PD, Carbone A, et al. Vildagliptin added to metformin on beta-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. *Diabetes Technol Ther.* 2012;14(6):475-484.
 105. Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. *Diabetes Res Clin Pract.* 2009;83(2):233-240.
 106. Rosenstock J, Foley JE, Rendell M, et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. *Diabetes Care.* 2008;31(1):30-35.
 107. Ahren B, Schweizer A, Dejager S, et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. *J Clin Endocrinol Metab.* 2009;94(4):1236-1243.
 108. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. *J Clin Endocrinol Metab.* 2004;89(5):2078-2084.
 109. Azuma K, Rádiková Z, Mancino J, et al. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. *J Clin Endocrinol Metab.* 2008;93(2):459-464.
 110. Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. *J Clin Endocrinol Metab.* 2007;92(4):1249-1255.
 111. Dalla Man C, Bock G, Giesler PD, et al. Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes. *Diabetes Care.* 2009;32(1):14-18.
 112. Famgren J, Persson M, Schweizer A, Foley JE, Ahrén B. Glucagon dynamics during hypoglycemia and food-rechallenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes. *Diabetes Obes Metab.* 2014;16(9):812-818.
 113. He YL, Serra D, Wang Y, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. *Clin Pharmacokinet.* 2007;46(7):577-588.
 114. He YL, Wang Y, Bullock JM, et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. *J Clin Pharmacol.* 2007;47(5):633-641.
 115. He YL, Valencia J, Zhang Y, et al. Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes. *Br J Clin Pharmacol.* 2010;70(1):34-42.
 116. Galvus (vildagliptin) [summary of product characteristics]. Camberley, UK: Novartis Europharm Limited; 2012.
 117. Hansen L, Iqbal N, Ekholm E, Cook W, Hirshberg B. Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy. *Endocr Pract.* 2014;20(11):1187-1197.
 118. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R; CV181-040 Investigators. Saxagliptin added to a sub-maximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. *Int J Clin Pract.* 2009;63(9):1395-1406.
 119. DeFronzo RA, Hissa MN, Garber AJ, et al; Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. *Diabetes Care.* 2009;32(9):1649-1655.
 120. Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E, Chen R; CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. *Diabetes Obes Metab.* 2009;11(6):611-622.
 121. Hollander P, Li J, Allen E, Chen R; CV181-013 Investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. *J Clin Endocrinol Metab.* 2009;94(12):4810-4819.
 122. Sjöstrand M, Iqbal N, Lu J, Hirshberg B. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes. *Diabetes Res Clin Pract.* 2014;105(2):185-191.
 123. Henry RR, Smith SR, Schwartz SL, et al. Effects of saxagliptin on beta-cell stimulation and insulin secretion in patients with type 2 diabetes. *Diabetes Obes Metab.* 2011;13(9):850-858.
 124. Onglyza (saxagliptin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2016.
 125. Rauch T, Graefe-Mody U, Deacon CF, et al. Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. *Diabetes Ther.* 2012;3(1):10.
 126. Yabe D, Eto T, Shiramoto M, et al. Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycemia in Japanese subjects with type 2 diabetes: a randomized, open-label, 2-arm parallel comparative, exploratory trial. *Diabetes Obes Metab.* 2017;19(3):442-447.
 127. Tradjenta (linagliptin) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2015.
 128. Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. *Curr Med Res Opin.* 2011;27(Suppl 3):21-29.
 129. Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging

- comparison with placebo, followed by a long-term extension study. *Curr Med Res Opin.* 2011;27(9):1781-1792.
130. Eliasson B, Möller-Goede D, Eeg-Olofsson K, et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. *Diabetologia.* 2012;55(4):915-925.
131. Van Raalte DH, van Genugten RE, Eliasson B, et al. The effect of alogliptin and pioglitazone combination therapy on various aspects of beta-cell function in patients with recent-onset type 2 diabetes. *Eur J Endocrinol.* 2014;170(4):565-574.
132. Nakamura Y, Inagaki M, Shimizu T, et al. Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study. *Nephron Clin Pract.* 2013;123(1-2):46-51.
133. Nesina (alogliptin) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America, Inc; 2016.
134. Derosa G, Franzetti IG, Querci F, et al. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial. *Pharmacotherapy.* 2013;33(8):817-826.
135. Diamant M, Nauck MA, Shagininian R, et al. Glucagon-like peptide I receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. *Diabetes Care.* 2014;37(10):2763-2773.
136. Drucker DJ, Buse JB, Taylor K, et al; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. *Lancet.* 2008;372(9645):1240-1250.
137. Buse JB, Rosenstock J, Sesti G, et al; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). *Lancet.* 2009;374(9683):39-47.
138. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. *J Clin Endocrinol Metab.* 2003;88(7):3082-3089.
139. Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. *Am J Health Syst Pharm.* 2005;62(2):173-181.
140. Cersosimo E, Gastaldelli A, Cervera A, et al. Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects. *J Clin Endocrinol Metab.* 2011;96(6):1763-1770.
141. Smits MM, Bunck MC, Diamant M, et al. Effect of 3 years of treatment with exenatide on postprandial glucagon levels. *Diabetes Care.* 2016;39(3):e42-e43.
142. Malloy J, Capparelli E, Gottschalk M, Guan X, Kothare P, Fineman M. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. *Clin Ther.* 2009;31(4):806-815.
143. Byetta (exenatide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2015.
144. Kapitza C, Forst T, Coester HV, Poitiers F, Ruus P, Hincelin-Mery A. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. *Diabetes Obes Metab.* 2013;15(7):642-649.
145. Rosenstock J, Hanefeld M, Shamanna P, et al. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). *J Diabetes Complications.* 2014;28(3):386-392.
146. Famgren J, Persson M, Ahren B. Effect of the GLP-1 receptor agonist lixisenatide on counterregulatory hormone responses to hypoglycemia in subjects with insulin-treated type 2 diabetes. *Diabetes Care.* 2016;39(2):242-249.
147. Becker RH, Stechl J, Mshid J, Kapitza C. Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes—a study in both people with type 2 diabetes and healthy subjects. *Diabetes Obes Metab.* 2014;16(9):793-800.
148. Adylin (lixisenatide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S., LLC; 2016.
149. Bydureon (exenatide extended release) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2015.
150. Feng P, Yu DM, Chen LM, et al. Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. *Acta Pharmacol Sin.* 2015;36(2):200-208.
151. Vilsbøll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. *Diabetes Care.* 2007;30(6):1608-1610.
152. Zinman B, Gerich J, Buse JB, et al; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). *Diabetes Care.* 2009;32(7):1224-1230. Erratum in *Diabetes Care.* 2010;33(3):692.
153. Kramer CK, Zinman B, Choi H, Connelly PW, Retnakaran R. The impact of chronic liraglutide therapy on glucagon secretion in type 2 diabetes: insight from the LIBRA trial. *J Clin Endocrinol Metab.* 2015;100(10):3702-3709.
154. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. *Diabetes.* 2004;53(5):1187-1194.
155. Hermansen K, Baekdal TA, During M, et al. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial. *Diabetes Obes Metab.* 2013;15(11):1040-1048.
156. Juhl CB, Hollingdal M, Sturis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. *Diabetes.* 2002;51(2):424-429.
157. Matsumoto S, Yamazaki M, Kadono M, et al. Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes. *J Clin Biochem Nutr.* 2013;53(1):68-72.
158. Victoza (liraglutide) [prescribing information]. Plainsboro, NJ: NovoNordisk A/S; 2016.
159. Seino Y, Inagaki N, Miyahara H, et al. A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus. *Curr Med Res Opin.* 2014;30(6):1095-1106.
160. Hompesch M, Jones-Leone A, Carr MC, et al. Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus. *Diabetes Obes Metab.* 2015;17(1):82-90.
161. Tanzeum (albiglutide) [prescribing information]. Wilmington, DE: GlaxoSmithKline LLC; 2016.
162. Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). *Diabetes Care.* 2015;38(12):2241-2249.
163. Trulicity (dulaglutide) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2015.
164. Nauck MA, Petrie JR, Sesti G, et al; Study 1821 Investigators. A phase 2, randomized, dose-finding study of the novel

- once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. *Diabetes Care*. 2016;39(2):231-241.
165. Okamoto A, Yokokawa H, Sanada H, Naito T. Changes in levels of biomarkers associated with adipocyte function and insulin and glucagon kinetics during treatment with dapagliflozin among obese type 2 diabetes mellitus patients. *Drugs R D*. 2016;16(3):255-261.
 166. Daniele G, Xiong J, Solis-Herrera C, et al. Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes. *Diabetes Care*. 2016;39(11):2036-2041.
 167. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. *J Clin Invest*. 2014;124(2):509-514. Erratum in *J Clin Invest*. 2014;124(5):2287.
 168. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. *J Clin Invest*. 2014;124(2):499-508. Erratum in *J Clin Invest*. 2014;124(4):1868.
 169. Wewer Albrechtsen NJ, Veedfald S, Plamboeck A, et al. Inability of some commercial assays to measure suppression of glucagon secretion. *J Diabetes Res*. 2016;2016:8352957.
 170. Pemicova I, Korbonits M. Metformin—mode of action and clinical implications for diabetes and cancer. *Nat Rev Endocrinol*. 2014;10(3):143-156.
 171. American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment. *Diabetes Care*. 2017;40(Suppl 1):S64-S74.
 172. Alengrin F, Grossi G, Canivet B, Dolais-Kitabgi J. Inhibitory effects of metformin on insulin and glucagon action in rat hepatocytes involve post-receptor alterations. *Diabetes Metab*. 1987;13(6):591-597.
 173. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. *Nature*. 2013;494(7436):256-260.
 174. Bansal P, Wang Q. Insulin as a physiological modulator of glucagon secretion. *Am J Physiol Endocrinol Metab*. 2008;295(4):E751-E761.
 175. Asmar M, Bache M, Knop FK, Madsbad S, Holst JJ. Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans? *J Clin Endocrinol Metab*. 2010;95(5):2367-2375.
 176. Kreyman B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. *Lancet*. 1987;2(8571):1300-1304.
 177. Nauck MA, Kleine N, Orskov C, Holst JJ, Wilms B, Creutzfeldt WW. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. *Diabetologia*. 1993;36(8):741-744.
 178. Christensen MB, Calanna S, Holst JJ, Vilsbøll T, Knop FK. Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes. *J Clin Endocrinol Metab*. 2014;99(3):E418-E426.
 179. Christensen M, Calanna S, Sparre-Ulrich AH, et al. Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes. *Diabetes*. 2015;64(1):72-78.
 180. Christensen M, Vedtofte L, Holst JJ, Vilsbøll T, Knop FK. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. *Diabetes*. 2011;60(12):3103-3109.
 181. Augstein P, Naselli G, Loudovaris T, et al. Localization of dipeptidyl peptidase-4 (CD26) to human pancreatic ducts and islet alpha cells. *Diabetes Res Clin Pract*. 2015;110(3):291-300.
 182. Omar BA, Liehua L, Yamada Y, Seino Y, Marchetti P, Ahren B. Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes. *Diabetologia*. 2014;57(9):1876-1883.
 183. Marchetti P, Lupi R, Bugiani M, et al. A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. *Diabetologia*. 2012;55(12):3262-3272.
 184. Degn KB, Brock B, Juhl CB, et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. *Diabetes*. 2004;53(9):2397-2403.
 185. Cervera A, Wajsborg E, Srivijitkamol A, et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. *Am J Physiol Endocrinol Metab*. 2008;294(5):E846-E852.
 186. Becker RH, Stechl J, Steintraesser A, Golor G, Pellissier F. Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects. *Diabetes Metab Res Rev*. 2015;31(6):610-618.
 187. Kalra S. Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology. *Diabetes Ther*. 2014;5(2):355-366.
 188. Cefalu WT. Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition. *J Clin Invest*. 2014;124(2):485-487.
 189. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. *Nat Med*. 2015;21(5):512-517.
 190. Solini A, Sebastiani G, Nigi L, Santini E, Rossi C, Dotta F. Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells. *Diabetes Metab*. 2017;43(6):512-520.
 191. Fralick M, Schneeweiss S, Paterno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. *N Engl J Med*. 2017;376(23):2300-2302.
 192. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. *Diabetes Care*. 2015;38(9):1638-1642.
 193. Goldenberg RM, Verna S, Perkins BA, Gilbert JD, Zinman B. Can the combination of incretin agents and sodium-glucose cotransporter 2 (SGLT2) inhibitors reconcile the yin and yang of glucagon? *Can J Diabetes*. 2017;41(1):6-9.
 194. Abdul-Ghani M. Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes? *Diabetes Care*. 2015;38(3):373-375.
 195. Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. *Diabetes Care*. 2015;38(3):394-402.
 196. DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. *Diabetes Care*. 2015;38(3):384-393.
 197. Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. *Diabetes Care*. 2015;38(3):376-383.
 198. Mathieu C, Ranetti AE, Li D, et al. Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. *Diabetes Care*. 2015;38(11):2009-2017.
 199. Matthei S, Catrinou D, Celinski A, et al. Randomized, double-blind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes. *Diabetes Care*. 2015;38(11):2018-2024.
 200. Mathieu C, Herrera Marmolejo M, González González JG, et al. Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes. *Diabetes Obes Metab*. 2016;18(11):1134-1137.

201. Jabbour SA, Hardy E, Sugg J, Parikh S; Study 10 Group. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. *Diabetes Care*. 2014; 37(3):740-750.
202. Frías JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. *Lancet Diabetes Endocrinol*. 2016;4(12):1004-1016.
203. Saroka RM, Kane MP, Busch RS, Watsky J, Hamilton RA. SGLT-2 inhibitor therapy added to GLP-1 agonist therapy in the management of T2DM. *Endocr Pract*. 2015;21(12): 1315-1322.
204. Fulcher G, Matthews DR, Perkovic V, et al; CANVAS trial collaborative group. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. *Diabetes Obes Metab*. 2016;18(1):82-91.
205. McGovern AP, Dutta N, Watters K, Munro N, Feher M. Additive weight loss effect with a combination of an oral sodium-glucose cotransporter 2 inhibitor and a glucagon-like peptide 1 agonist in type 2 diabetes [abstract]. *Diabet Med*. 2015;32(Suppl 1):2-3.
206. Lundkvist P, Sjöström CD, Amini S, Pereira MJ, Johnsson E, Eriksson JW. Dapagliflozin once-daily and exenatide once-weekly dual therapy: a 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes. *Diabetes Obes Metab*. 2017;19(1):49-60.
207. ClinicalTrials.gov. Effect of combined incretin-based therapy plus canagliflozin on glycemic control and the compensatory rise in hepatic glucose production in type 2 diabetic patients (ClinicalTrials.gov identifier: NCT02324842). <https://clinicaltrials.gov/ct2/show/NCT02324842>. Accessed March 1, 2017.
208. ClinicalTrials.gov. A study of dulaglutide (LY2189265) in participants with type 2 diabetes mellitus (AWARD-10) (ClinicalTrials.gov identifier: NCT02597049). <https://clinicaltrials.gov/ct2/show/record/NCT02597049>. Accessed March 1, 2017.
209. Lotfi M, Kalasz H, Szalai G, Singh J, Adeghate E. Recent progress in the use of glucagon and glucagon receptor antagonists in the treatment of diabetes mellitus. *Open Med Chem J*. 2014; 8:28-35.
210. Lee YH, Wang MY, Yu XX, Unger RH. Glucagon is the key factor in the development of diabetes. *Diabetologia*. 2016; 59(7):1372-1375.
211. Yan H, Gu W, Yang J, et al. Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys. *J Pharmacol Exp Ther*. 2009;329(1):102-111.
212. Kazda CM, Ding Y, Kelly RP, et al. Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12- and 24-week phase 2 studies. *Diabetes Care*. 2016;39(7):1241-1249.
213. Bergman A, Tan B, Somayaji VR, Calle RA, Kazierad DJ. A 4-week study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of the glucagon receptor antagonist PF-06291874 administered as monotherapy in subjects with type 2 diabetes mellitus. *Diabetes Res Clin Pract*. 2017; 126:95-104.
214. Engel SS, Xu L, Andryuk PJ, et al. Efficacy and tolerability of MK-0893, a glucagon receptor antagonist (GRA) in patients with type 2 diabetes (T2DM) [abstract 309-OR]. *Diabetes*. 2011;60(Suppl 1):A85.
215. Ruddy M, Pramanik B, Luncemford J, et al. Inhibition of glucagon-induced hyperglycemia predicts glucose lowering efficacy of a glucagon antagonist, MK-0893, in type 2 diabetes (T2DM). *Diabetes*. 2011;60(Suppl 1):A85-A86.
216. Guzman CB, Zhang XM, Liu R, et al. Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes. *Diabetes Obes Metab*. 2017;19(11):1521-1528.
217. Kazda CM, Frias J, Foga I, et al. Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes. *Diabetes Obes Metab*. 2017;19(8):1071-1077.
218. Guan HP, Yang X, Lu K, et al. Glucagon receptor antagonism induces increased cholesterol absorption. *J Lipid Res*. 2015; 56(11):2183-2195.
219. Day JW, Gelfanov V, Smiley D, et al. Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents. *Biopolymers*. 2012;98(5):443-450.
220. Day JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. *Nat Chem Biol*. 2009;5(10):749-757.
221. Pocai A, Carrington PE, Adams JR, et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. *Diabetes*. 2009;58(10):2258-2266.
222. Clemmensen C, Chabenne J, Finan B, et al. GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. *Diabetes*. 2014;63(4):1422-1427.